LONDON --Hikma Pharmaceuticals (ISE: HIK.L) soared 42 pence, or 6%, to 767 pence in early trading after the pharmaceutical specialist published its half-year results.
Hikma reported six-month sales up 35% to $532 million and adjusted profits up 37% to $82 million. The overall performance was assisted by $325 million spent on acquisitions during 2011. Hikma claimed growth excluding the effect of acquisitions was about 7%.
The dividend was lifted 9% to $0.06 per share.
Hikma's three divisions experienced mixed fortunes during the first six months of 2012. The group's branded products experienced underlying growth of 12%, while "injectables" recorded underlying growth of 26%. However, additional compliance work and increased pricing pressure caused Hikma's generic revenue to slump 27%.
Said Darwazah, Hikma's chief executive, said:
We have had a strong start to the year in our Branded and Injectables businesses. I am pleased with the growth we have achieved in our key markets this year. Our global Injectables business continues to deliver extremely strong growth, as we benefit from our increased scale and continued investment in quality and products. In our Generics business, where operations have been disrupted by additional compliance work, we expect sales to gradually improve in the second half.
Overall the Group is performing well and the outlook is positive for the second half. I am pleased to be able to reiterate our Group guidance of around 20% revenue growth for the full year.
Mr. Darwazah's optimism for the rest of the year should extend Hikma's respectable track record. Since the firm floated during 2005, annual sales have surged from $262 million to $1,056 million while profits have advanced from $69 million to $168 million.
Meanwhile, the share price has more than tripled from 250 pence -- and trounced the wider market -- during the last seven years.
If you are keen to earn equally handsome returns from high-growth companies such as Hikma, this free Motley Fool report could help you on your way. The report explains how spotting companies with great expansion potential is a vital step on the path to a magic 1,000,000-pound portfolio. Maybe one day, a company such as Hikma could transform your wealth.
Just click here to download this "Millionaire" report today. But hurry, all Fool reports are free for a limited time only.
Investing is by no means easy in today's uncertain economy. That's why we've published "The Market's Top Sectors" -- our guide to three favorable industries. This free report will be dispatched immediately to your inbox.
Further Motley Fool investment opportunities:
The article Pharmaceutical Group Set for 20% Growth originally appeared on Fool.com.
Maynard Paton does not own any share mentioned in this article.The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.